Ipsen SA

101,00

23-мая-25 08:29:56

15 мин. задержка

Акции

-0,90

-0,88%

Сегодняшний диапазон

100,00 - 102,50

ISIN

FR0010259150

Источник

Cboe

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 ноя 2024 09:00:00 Источник Nasdaq GlobeNewswire
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

22 окт 2024 22:00:00 Источник Nasdaq GlobeNewswire
Ipsen receives its second Shingo Prize for operational excellence

14 окт 2024 09:00:00 Источник Nasdaq GlobeNewswire
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 окт 2024 09:00:00 Источник Nasdaq GlobeNewswire
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

23 сен 2024 04:13:10 Источник Nasdaq GlobeNewswire
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

20 сен 2024 05:57:57 Источник Nasdaq GlobeNewswire
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

16 сен 2024 05:45:00 Источник Nasdaq GlobeNewswire
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

15 сен 2024 05:45:00 Источник Nasdaq GlobeNewswire
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

04 сен 2024 09:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024

13 авг 2024 09:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024

06 авг 2024 09:00:00 Источник Nasdaq GlobeNewswire
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

05 авг 2024 09:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024

30 июл 2024 09:00:00 Источник Nasdaq GlobeNewswire
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

26 июл 2024 03:46:22 Источник Nasdaq GlobeNewswire
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)

25 июл 2024 05:18:23 Источник Nasdaq GlobeNewswire
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

24 июл 2024 22:00:00 Источник Nasdaq GlobeNewswire
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

24 июл 2024 21:58:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

23 июл 2024 09:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

16 июл 2024 09:00:00 Источник Nasdaq GlobeNewswire
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

10 июл 2024 22:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.